176 related articles for article (PubMed ID: 17680218)
1. Splenic marginal zone lymphoma with and without villous lymphocytes.
Matutes E
Curr Treat Options Oncol; 2007 Apr; 8(2):109-16. PubMed ID: 17680218
[TBL] [Abstract][Full Text] [Related]
2. Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes.
Troussard X; Cornet E
Curr Treat Options Oncol; 2007 Apr; 8(2):97-108. PubMed ID: 17634839
[TBL] [Abstract][Full Text] [Related]
3. Splenic marginal zone lymphoma: disease features and management.
Matutes E
Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
[TBL] [Abstract][Full Text] [Related]
4. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of splenic lymphoma with villous lymphocytes by rituximab and laparoscopic splenectomy].
Fujita T; Asagoe K; Sakoda H
Rinsho Ketsueki; 2003 Apr; 44(4):249-53. PubMed ID: 12784658
[TBL] [Abstract][Full Text] [Related]
6. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma.
Catovsky D; Matutes E
Semin Hematol; 1999 Apr; 36(2):148-54. PubMed ID: 10319383
[TBL] [Abstract][Full Text] [Related]
7. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
8. Marginal zone-related neoplasms of splenic and nodal origin.
Arcaini L; Paulli M; Boveri E; Magrini U; Lazzarino M
Haematologica; 2003 Jan; 88(1):80-93. PubMed ID: 12551831
[TBL] [Abstract][Full Text] [Related]
9. [Splenic marginal zone lymphoma].
Dimopoulos K; Pedersen M
Ugeskr Laeger; 2012 Oct; 174(40):2383-6. PubMed ID: 23031300
[TBL] [Abstract][Full Text] [Related]
10. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
[TBL] [Abstract][Full Text] [Related]
11. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
12. Splenic marginal zone lymphoma.
Franco V; Florena AM; Iannitto E
Blood; 2003 Apr; 101(7):2464-72. PubMed ID: 12446449
[TBL] [Abstract][Full Text] [Related]
13. Treatment of splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.
Mihăilă RG
World J Gastroenterol; 2016 Jul; 22(27):6214-23. PubMed ID: 27468211
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
16. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
[TBL] [Abstract][Full Text] [Related]
17. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
18. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.
Parry-Jones N; Matutes E; Gruszka-Westwood AM; Swansbury GJ; Wotherspoon AC; Catovsky D
Br J Haematol; 2003 Mar; 120(5):759-64. PubMed ID: 12614206
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
20. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients.
Iannitto E; Ambrosetti A; Ammatuna E; Colosio M; Florena AM; Tripodo C; Minardi V; Calvaruso G; Mitra ME; Pizzolo G; Menestrina F; Franco V
Cancer; 2004 Nov; 101(9):2050-7. PubMed ID: 15389479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]